IBEX Technologies, Inc. (IBT) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

200

Shareholding (Jun 2023)

FII

0.00%

Held by 0 FIIs

DII

12.0%

Held by 0 DIIs

Promoter

26.76%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Medical Specialties

Market cap

CAD 35 Million (Micro Cap)

P/E

9.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.59

Return on Equity

27.93%

Price to Book

2.48

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Jan 2024)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

26.32%

6 Months

45.45%

1 Year

84.62%

2 Years

182.35%

3 Years

336.36%

4 Years

1052.0%

5 Years

700.0%

IBEX Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.29%

EBIT Growth (5y)

21.43%

EBIT to Interest (avg)

1.05

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.59

Sales to Capital Employed (avg)

0.67

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

32.55%

ROE (avg)

14.29%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.48

EV to EBIT

17.24

EV to EBITDA

13.04

EV to Capital Employed

4.63

EV to Sales

3.36

PEG Ratio

0.05

Dividend Yield

ROCE (Latest)

26.87%

ROE (Latest)

27.93%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2023

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jan'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jan 2024 is -9.52% vs 16.67% in Oct 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jan 2024 is -100.00% vs -63.64% in Oct 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jan'24",
        "Oct'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.90",
          "val2": "2.10",
          "chgp": "-9.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.30",
          "val2": "0.70",
          "chgp": "-57.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "0.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "81.70%",
          "val2": "295.40%",
          "chgp": "-21.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2023 is -5.06% vs 49.06% in Jul 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2023 is 129.41% vs 112.50% in Jul 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'23",
        "Jul'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.50",
          "val2": "7.90",
          "chgp": "-5.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.50",
          "val2": "2.60",
          "chgp": "-42.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.90",
          "val2": "1.70",
          "chgp": "129.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "147.90%",
          "val2": "287.30%",
          "chgp": "-13.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jan'24 - QoQ

Jan'24

Oct'23

Change(%)

Net Sales

1.90

2.10

-9.52%

Operating Profit (PBDIT) excl Other Income

0.30

0.70

-57.14%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.00

0.80

-100.00%

Operating Profit Margin (Excl OI)

81.70%

295.40%

-21.37%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jan 2024 is -9.52% vs 16.67% in Oct 2023

Consolidated Net Profit

QoQ Growth in quarter ended Jan 2024 is -100.00% vs -63.64% in Oct 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jul'23

Jul'23

Jul'22

Change(%)

Net Sales

7.50

7.90

-5.06%

Operating Profit (PBDIT) excl Other Income

1.50

2.60

-42.31%

Interest

0.10

Exceptional Items

0.00

0.10

-100.00%

Consolidate Net Profit

3.90

1.70

129.41%

Operating Profit Margin (Excl OI)

147.90%

287.30%

-13.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jul 2023 is -5.06% vs 49.06% in Jul 2022

Consolidated Net Profit

YoY Growth in year ended Jul 2023 is 129.41% vs 112.50% in Jul 2022

All Annual Results

Company CV

About IBEX Technologies, Inc.

IBEX Technologies, Inc.

Medical Specialties

IBEX Technologies Inc., through its subsidiaries, IBEX Pharmaceuticals Inc. and BioResearch Products Inc., manufactures and markets enzymes for biomedical use. The Company also manufactures and markets a series of arthritis assays, which enable the study of both the synthesis and degradation of cartilage components. It operates through the production and sale of diagnostic products segment. Its products include IB-C2C-HUSA, C2C Assay, CPII Assay, C1-2C Assay and CS-846 Assay. It provides various individual collagen associated antibodies, such as Ab1320-Rabbit Polyclonal Antibody; Type IX Collagen Antibody, and C1-2C Antibody (Col 2 3/4C short Antibody). Its diagnostic microtiter enzyme-linked immunosorbent assays include C2C-Collagen Type II Cleavage Assay; IB-C2C-HUSA-IBEX C2C Human Urine Sandwich Assay; C1,2C-Collagen Type I and II Cleavage Assay (Col 2 3/4C short antibody); CPII-Procollagen Type II C-Propeptide Assay, and CS846-Aggrecan Chondroitin Sulfate 846 Epitope Assay.

Company Coordinates

Company Details

Suite 100, 5485 Pare Street , MONTREAL QC : H4P 1P7

Tel: 1 514 3444004

https://www.ibex.ca/

Registrar Details